The use of gabapentin in the treatment ofkeratoconus

Phase 2

• Conditions: Postoperative pain; C23.550.767.700

• Registration Number: RBR-23r5mc
• Lead Sponsor: niversidade do Oeste de Santa Catarina

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-22
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Twelve participants with progressive keratoconus who underwent Crosslinking were selected, of both sexes, aged 10 to 40 years.

Exclusion Criteria

Intellectual inability to answer the questionnaire applied in the postoperative period.
Allergy to the drug Gabapentin.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
expected outcome 1: Gabapentin is expected to be effective in postoperative pain control after corneal CXL (fast - 10 minutes) compared to placebo.;Outcome presented 1: It was observed that gabapentin did not demonstrate efficacy in pain control in the postoperative period after corneal CXL (fast - 10 minutes) compared to placebo.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are not expected.